1. Introduction {#s0005}
===============

Cancer is the uncontrolled growth and spread of cells [@bb0005] and it has become a serious danger to human beings [@bb0010]. However, its survival chance is still basically dependent on tumor types, time of diagnosis and of course, clinical therapies [@bb0015]. The detection of tumor markers has been widely used to screen cancers on a population basis [@bb0020]. Although it contributes to cancer diagnosis and clinical therapies, tumor marker detection results cannot act as a direct evidence to confirm cancer presence because of the lack of detection specificity. In order to increase the detection specificity, several tumor markers are combined to detect cancers and improved results are acquired. However, joint detection of tumor markers is much more complicated than single marker detection and raises the requirement to detection methods. Thus, the need for effective methods to detect tumor marker combinations rapidly, sensitively and reliably is consequently subjected to broad interest.

Imaging ellipsometry [@bb0025], [@bb0030] is derived from the conventional ellipsometry by introducing an expanded beam and a CCD camera instead of the traditional narrow beam and the photodiode detector. These changes render the unique advantages of conventional ellipsometry and microscope to imaging ellipsometry. Imaging ellipsometry is not only a label-free characterization technique with high resolution but it also owns a large field of view, providing the capability to detect a considerable area at the same time [@bb0035], [@bb0040]. The concept of imaging ellipsometry biosensor (IEB) for visualization of biomolecular interactions was proposed in 1995 [@bb0045], [@bb0050]. With the developments these years, it has become automatic equipment [@bb0055], [@bb0060] for protein interaction analysis. IEB is primarily composed of a microfluidic reactor [@bb0065] and an imaging ellipsometer [@bb0050], [@bb0070]. The microfluidic reactor is served to fabricate a patterned protein microarray; while the imaging ellipsometer is used to measure the surface mass concentration distribution of a protein microarray. So far, IEB has accumulated several application experiences in biological and clinical fields, for instance, five markers of hepatitis B virus [@bb0075], tumor markers [@bb0080], [@bb0085], phage M~13~KO~7~ [@bb0090], severe acute respiratory syndrome virus [@bb0095], avian influenza virus [@bb0100] and ricin antibody identification [@bb0105].

Hepatocellular carcinoma is one of most common cancers in developing countries [@bb0010] and the average survival period is only about several months. Accurate diagnosis in an early stage has a potential to extend the survival period effectively. α-Fetoprotein (AFP) [@bb0110] and α-[l]{.smallcaps}-fucosidase (AFU) [@bb0115] are considered as two specific tumor markers for hepatocellular carcinoma; while ferritin [@bb0120] is commonly used to monitor lesion in liver tissue. In this investigation, the quantitative detection of these three tumor markers simultaneously has been performed with IEB as a trial.

2. Materials and methods {#s0010}
========================

2.1. IEB and its detection principle {#s0015}
------------------------------------

During the last decade, IEB has been updated and improved in our laboratory [@bb0055], [@bb0060], [@bb0070]. Now, it is mainly composed of a microfluidic reactor and an imaging ellipsometer.

The microfluidic reactor integrating 48 independent flow channels is used to fabricate protein microarrays by a series of continuous processes, including the surface patterning, the ligand immobilization, the surface blocking and the analyte solution delivery as well as the surface rinsing [@bb0060]. When a silicon wafer substrate is placed on the top of the reactor, it forms the 48 independent reaction cells and each cell has an independent inlet and outlet for the solution delivery. The inlet channels are connected to a sample reservoir and the outlet channels are connected with the pumps offering negative pressure. With the microfluidic reactor, different solutions can be delivered to the appointed reaction cells and afterwards a microarray can be fabricated in a precise pattern.

The imaging ellipsometer acts as the data acquisition of a protein microarray. Imaging ellipsometry is an enhancement of the standard single beam ellipsometry, which combines the power of ellipsometry with microscopy and is worked in the off-null mode. It can be utilized for the visualization of surface mass concentration distribution of protein layers. A slight variation of surface mass concentration can be remarkably distinguished by the imaging ellipsometer and the result is represented in gray-scale images. Upon the high sensitivity requirements to observe biomolecule interactions, the imaging ellipsometer has been improved by the introduction of a spectroscopic light source and a low noise imaging device [@bb0060] with the optimization of polarization settings.

The principle to detect protein interactions with IEB is shown in [Fig. 1](#f0010){ref-type="fig"} [@bb0055]. A ligand is immobilized on a surface to form a biosensing surface to a receptor which exists in an analyte solution. When the biosensing surface is exposed to the analyte solution, ligands and receptors can interact specifically with each other to form complexes due to their affinity. The surface mass concentration of protein layers will change during this recognition process. With the visualization of imaging ellipsometry, the change can be determined quantitatively in the format of gray-scale images. In that case, the existence of the receptor in the analyte solution can be verified.Fig. 1IEB principle to detect protein interactions. The polarized light is incident on a protein layer and the reflective beam carries the information of the protein layer, for example its surface mass concentration. Ligand molecules can react with their receptors and form complexes on the biosensing interface, resulting in the change of layer surface mass concentration. This variation is embodied in reflection light intensity and can be quantitatively recorded in the format of gray-scale image [@bb0055].

2.2. Chemicals, samples and substrates {#s0020}
--------------------------------------

Silicon wafers are provided by Beijing GRINM Materials Company. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), succinic anhydride and aminopropyl-triethoxysilane (APTES) are purchased from Acros Organics. N-Hydroxy-succinimide (NHS), blocking buffer, phosphate buffered saline containing 0.05% Tween-20 (PBST) and protein A from *Staphylococcus aureus* are bought from Sigma-Aldrich. AFP and AFP rabbit monoclonal antibody are purchased from Sigma-Aldrich. AFU and its mouse monoclonal antibody are obtained from Abcam. Recombined ferritin and its goat monoclonal antibody are purchased from Sigma-Aldrich. 82 human serum samples including 41 healthy people and 41 hepatocellular carcinoma patients are collected in Shandong Academy of Medical Sciences. Their detailed clinical background and commercial immunoassay kit detection results are presented in [Table A.1](#t0015){ref-type="table"}, [Table A.2](#t0020){ref-type="table"} in [Appendix A](#s0065){ref-type="sec"}. Deionized water is produced by ion exchange demineralization, followed by passing through a Milli-Q plus system from Millipore.

2.3. Silicon wafer preparation and surface modification {#s0025}
-------------------------------------------------------

Silicon wafer is used as a solid substrate for IEB. Due to the throughput need of 48 independent units, the silicon slides are cut into 25 × 13 mm^2^ rectangular pieces. Then, in order to wash out the organic and inorganic contamination, silicon wafers are cleaned by a fresh piranha solution for 30 min. After being thoroughly rinsed with deionized water and pure ethanol, silicon wafers are incubated in an ethanol solution of APTES (5% APTES and 95% pure ethanol) for 2 h at room temperature. Followed by intensive rinsing in pure ethanol, silicon wafers silanized with APTES are treated with over-saturated succinic anhydride in ethanol for at least 3 h. After rinsing with pure ethanol, silicon wafers are stored in pure ethanol. The detailed surface modification process above has been described in a review article [@bb0125].

2.4. Establishing AFP, AFU and ferritin calibration curves {#s0030}
----------------------------------------------------------

Quantitative detection of AFP, AFU and ferritin is based on establishing their calibration curves. Monoclonal antibodies of AFP, AFU and ferritin are used as the ligands to construct a sensing surface for the joint detection of AFP, AFU and ferritin. In order to preserve their bioactivity, protein A is applied for the oriented immobilization of AFP, AFU and ferritin antibodies, since protein A can bind the Fc portion of an antibody specifically and have the Fab part exposed outside the substrate. Antibody Fab part acts as the binding site to recognize against an antigen specifically. Maintaining antibody Fab part outward can lead to better performance to recognize and capture its corresponding antigen in the analyte solution.

Ligand surface concentration is a pivot to decide the amount of analyte to be captured, further influencing detection performance, for example, detection sensitivity and range. Less ligand results in the scarcity of analyte binding sites; whereas excess situation affects ligand bio-activity and increases the steric hindrance. In order to improve the detection performance, the concentrations of AFP, AFU and ferritin antibodies as the ligands have been optimized in advanced. A series of concentrations of AFP, AFU and ferritin antibodies are added to the protein A modification surface to fabricate AFP, AFU and ferritin sensing surfaces and then tested by AFP, AFU and ferritin standard solutions. The ligand concentration obtained from the maximum increase of biosensor signal is chosen as the optimized value to construct the biosensing surfaces.

The detailed procedures to establish AFP, AFU and ferritin calibration curves are listed as follows. Firstly, a modified silicon wafer is placed into the microfluidic reactor. A mixture solution prepared with 0.05 mol/mL NHS and 0.2 mol/mL EDC in deionized water is passed through the surface at a flow rate of 5 μL/min for 5 min. With NHS and EDC, carboxyl groups on the substrate form sulfo-NHS-ester and are able to react with the amino groups of protein A. Then, protein A at 0.2 mg/mL is adsorbed on the substrate at a flow rate of 1 μL/min for 15 min. AFP, AFU and ferritin antibodies are immobilized by protein A for 20 min at a flow rate of 1 μL/min. After that, the surface is blocked by IgG from the same species to the ligands and blocking buffer, respectively. Such IgG can be bound to protein A, but it cannot react with AFP, AFU, ferritin and human serum. It is used to occupy protein A left on the sensing surface and prevent the specific binding between protein A and antibody in the analyte solution. Blocking buffer can also bind to the biosensing surface and avoid the non-specific adsorption with the addition of analyte solution, especially, serum samples. After surface blocking, AFP, AFU and ferritin standard samples are delivered into their corresponding sensing surfaces at a flow rate of 1 μL/min for 20 min. Finally, rinsed with plenty of PBST and completely dried under nitrogen, the microarray is sampled and stored into a gray-scale image by the imaging ellipsometer.

2.5. Quantitative detection of human serum samples {#s0035}
--------------------------------------------------

In terms of AFP, AFU and ferritin detection range determined by the calibration curves, serum samples are diluted properly before detections. If the result of a serum sample still exceeds the detection range, it will be diluted and then detected once more until its detection result is within the detection range. AFP, AFU and ferritin concentrations in one serum sample are detected in the same assay which can be used to accommodate up to 16 serum samples. The detection procedure is strictly followed to the process to establish AFP, AFU and ferritin calibration curves. Each serum sample is measured three times, and then AFP, AFU and ferritin concentrations in serum samples are calculated by their calibration curves.

3. Results {#s0040}
==========

3.1. AFP, AFU and ferritin calibration curves {#s0045}
---------------------------------------------

Optimized detection procedures are likely to result difference for AFP, AFU and ferritin. However, because the solution delivery process to fabricate a protein microarray in the microfluidic reactor is controlled by the same peristaltic pump, some parameters, for example detection rate and duration time for an assay, cannot be adjusted independently and has to be compromised to a unified value. By preliminary experiments, different detection procedure parameters have been compared and a compromised yet optimized condition has been utilized to establish AFP, AFU and ferritin calibration curves (shown in [Section 2.4](#s0030){ref-type="sec"}). Meanwhile, ligand concentration is also needed to be optimized in order to obtain good detection sensitivity and wide detection range. A series of concentrations of AFP, AFU and ferritin antibodies have been screened to find out the optimized value to construct their sensing surface and the optimization concentration values for AFP, AFU and ferritin antibodies are 120 μg/mL, 80 μg/mL and 60 μg/mL, respectively. In addition, for achieving the best image contrast for AFP, AFU and ferritin detection, the incidence angle in which the light beam is directed to the silicon substrate, the azimuth angles of polarizer, compensator and analyzer in ellipsometric setup are fixed at 75° [@bb0130], 82.2°, 45.0° and 10.8°, respectively.

AFP, AFU and ferritin standard samples at different concentrations have been added to their sensing surfaces for establishing their calibration curves (shown in [Fig. 2](#f0015){ref-type="fig"} ). By multi-parameter fitting, the relationship between IEB signals in gray-scale value and tumor marker concentrations can be represented by the regression equations (listed in [Table 1](#t0005){ref-type="table"} ).Fig. 2The calibration curves for quantitative detection of AFP, AFU and ferritin. The calibration curves show that the relationship between IEB signals and the concentrations of AFP, AFU and ferritin is y = 13.4 log(x) + 79.7, y = 24.6 log(x) + 88.1, and y = 14.5 log(x) + 76.8, respectively, and the detection limit of AFP, AFU and ferritin is content to the clinical test standard.Table 1Calibration curves for quantitative detection of AFP, AFU and ferritin.Regression equationsLinear detection rangeLimit of detectionAFPy = 13.4 log(x) + 79.71--64 ng/mL2 ng/mLAFUy = 24.6 log(x) + 88.11--64 U/L1 U/LFerritiny = 14.6 log(x) + 76.85--160 ng/mL5 ng/mL[^1]

The limit of detection (LOD) value for AFP, AFU and ferritin is defined as their lowest detection concentrations while an increase caused by the antibody--antigen complex is over 3 times of standard deviation of the blank control [@bb0135], [@bb0140]. Protein A is used to be the blank control and its standard deviation of 20 replicates is 1.0 in gray-scale value. Therefore, LOD values for AFP, AFU and ferritin detection achieve at 2 ng/mL, 1 U/L and 5 ng/mL, respectively, and meet the clinical detection requirements.

3.2. Serum sample detection {#s0050}
---------------------------

Eighty-two human serum samples gathered from 41 healthy persons and 41 hepatocellular carcinoma patients have been tested strictly according to the protocol in establishing the calibration curves for quantitative detection. Each serum has been detected three times and the result in gray-scale value is converted to tumor marker concentration in terms of the relationship obtained in the corresponding calibration curve. All the detection results for the eighty-two serum samples are listed in [Table A.3](#t0025){ref-type="table"}, [Table A.4](#t0030){ref-type="table"}, [Table A.5](#t0035){ref-type="table"} in [Appendix A](#s0065){ref-type="sec"}, and an example of detection result in gray-scale image for 13 serum samples is presented in [Fig. 3](#f0020){ref-type="fig"} .Fig. 3An example of IEB result in gray-scale image. Seven sera from hepatocellular carcinoma patients, six sera from healthy persons as well as the negative and positive controls have been detected for three tumor markers AFP, AFU and ferritin in the same substrate.

IEB results are compared with those of the commercial approaches in clinical diagnosis and their differences are statistically evaluated by correlation analysis (shown in [Fig. 4](#f0025){ref-type="fig"} ). The Pearson correlation coefficients [@bb0145] for AFP, AFU and ferritin detection are 0.544, 0.949 and 0.879, respectively. It is indicated that results of IEB and clinical tests have significant statistical relevance at the level of 0.01. In other words, IEB results are in good agreement with clinical methods.Fig. 4Results of IEB and clinical methods for AFP, AFU and ferritin detection of eighty-two serum samples. The Pearson correlation coefficients for AFP, AFU and ferritin detection are 0.544, 0.949 and 0.879, respectively, suggesting IEB results are in good agreement with clinical methods.

3.3. Joint detection performance {#s0055}
--------------------------------

Receiver operating characteristic (ROC) analysis [@bb0150] is used to estimate the detection specificity in clinical diagnosis by calculating the area under the ROC curve (AUC) value. If the AUC value is bigger than 0.5, the negative and the positive can be classified effectively by a detection method. Higher AUC value indicates better detection performance.

The ROC curve for hepatocellular carcinoma detection with IEB is shown in [Fig. 5](#f0030){ref-type="fig"} and the AUC value is listed in [Table 2](#t0010){ref-type="table"} . The AUC value of AFP and AFU is bigger than 0.5, so the two tumor markers play an effective role to distinguish the patients from the healthy people. However, AUC value of ferritin is less than 0.5, indicating that it is not related to hepatocellular carcinoma detection. In that case, only AFP and AFU are combined together to form a joint marker. Compared with the single marker detection, AUC value of the joint marker detection increases remarkably, suggesting the improvement on detection specificity for hepatocellular carcinoma diagnosis.Fig. 5The ROC curve for hepatocellular carcinoma detection with IEB and clinical methods.Table 2AUC value of clinical method and IEB for hepatocellular carcinoma detection.TMClinic methodIEBAFP0.8110.845AFU0.7400.780Ferritin0.4190.481AFP + AFU0.8270.972

The ROC curve for hepatocellular carcinoma detection of the clinical methods is shown in [Fig. 5](#f0030){ref-type="fig"}. Its detection results show the same tendency to those of IEB. Only AFP and AFU are considered as specific tumor markers for hepatocellular carcinoma and contributed to the joint marker. However, no matter the single marker detection or the joint marker detection, the AUC value of the clinical method is slightly lower than IEB, presenting IEB detection performance for hepatocellular carcinoma as having an advantage over the clinical methods.

4. Conclusions {#s0060}
==============

IEB has been developed as a quantitative approach for the joint detection of hepatocellular carcinoma markers. By ROC curve analysis, AFP and AFU play a positive role to distinguish hepatocellular carcinoma patients from the healthy ones and are combined to the joint detection marker. The detection range and the detection limit are adequate for clinical diagnosis requirements. Eighty-two sera have been tested with IEB and their results are validated by commercial clinical methods. The joint detection is proved to improve the specificity for hepatocellular carcinoma detection.

 {#s0065}

Table A.1Clinical information and clinical detection results of 82 serum samples.SampleAgeGenderAFPAFUFerritinDetection dateClinic diagnosisH0142F2.519.5262.22010/1/5HCC +H0251F9.017.0223.12010/1/5HCC +H0369M5.117.9199.32010/1/8HCC +H0445M3.227.3216.32010/1/8HCC +H0573M4.629.0242.82010/1/12HCC +H0648M8.843.1341.52010/1/19HCC +H0748F1.818.7234.12010/1/20HCC +H0855M7.419.5253.22010/1/20HCC +H0940M8.712.2286.32010/1/21HCC +H1060M7.521.1288.22010/1/25HCC +H1155M16.740.8311.32010/2/1HCC +H1249M10.941.6193.22010/2/2HCC +H1351M9.221.4339.02010/2/4HCC +H1455M2.824.5212.52010/2/4HCC +H1566F1091.045.6174.62010/2/5HCC +H1638F2541.029.1233.72010/2/8HCC +H1764M3.628.2203.62010/2/21HCC +H1889M1.926.2269.52010/3/2HCC +H1929M2.312.0183.92010/3/3HCC +H2075F7.530.3149.92010/3/3HCC +H2141M2356.026.6287.52010/3/3HCC +H2244M1453.040.1286.72010/3/5HCC +H2366F16,380.023.2209.92010/3/5HCC +H2464M15,910.031.4225.12010/3/5HCC +H2570M88,130.026.6205.72010/3/8HCC +H2662M14.926.9241.72010/3/8HCC +H2772M2.517.6234.92010/3/11HCC +H2851M36,430.046.2336.12010/3/15HCC +H2962M158.318.4292.22010/3/18HCC +H3054M1125.044.6358.42010/3/22HCC +H3150M4.118.5235.52010/3/23HCC +H3246M1873.023.3119.92010/3/29HCC +H3335F11.418.3198.82010/3/29HCC +H3450M47.028.3193.82010/3/29HCC +H3555F1029.043.2199.32010/4/2HCC +H3684M14.827.2224.52010/4/2HCC +H3756M2.311.1325.32010/4/2HCC +H3884M2.311.7310.72010/4/6HCC +H3961F2.217.6207.02010/4/6HCC +H4039F6.314.9294.02010/4/6HCC +H4148M3.415.9284.12010/4/6HCC +N0145M3.015.6240.32009/11/6HealthyN0245M1.810.6314.42009/11/6HealthyN0348M2.416.7260.72009/11/6HealthyN0440M6.314.9292.12009/11/6HealthyN0549F2.517.8241.92009/11/6HealthyN0641M5.832.3368.32009/11/6HealthyN0754F2.431.7288.22009/11/6HealthyN0840F2.217.7283.22009/11/6HealthyN0951F2.719.4407.92009/11/6HealthyN1058M2.618.4300.22009/11/6HealthyN1146M3.933.5278.62009/11/6HealthyN1246F2.425.0390.22009/11/6HealthyN1354F3.525.5219.02009/11/6HealthyN1446F1.619.4168.12009/11/6HealthyN1546M3.118.5319.42009/11/6HealthyN1650M3.517.8254.32009/11/19HealthyN1738M1.820.2177.52009/11/20HealthyN1849M2.016.1310.12009/11/20HealthyN1953F4.123.9244.52009/12/9HealthyN2062M2.216.1290.12009/12/9HealthyN2161M3.213.8237.12009/12/9HealthyN2263M3.019.8257.72009/12/9HealthyN2359F3.010.8411.12009/12/9HealthyN2455F2.516.1345.22009/12/9HealthyN2543F3.822.7201.22009/12/11HealthyN2651F3.913.5405.22009/12/11HealthyN2747M2.317.4429.22009/12/11HealthyN2853M3.516.2397.22009/12/11HealthyN2948F2.416.3310.62009/12/11HealthyN3040M2.416.0204.22009/12/11HealthyN3156F2.423.4113.42009/12/11HealthyN3257M6.224.6167.52009/12/11HealthyN3346M4.314.3211.32009/12/14HealthyN3455M2.115.9188.42009/12/14HealthyN3541F1.925.5394.32009/12/14HealthyN3654F2.013.2125.42009/12/14HealthyN3755F1.412.2109.42009/12/17HealthyN3869M5.910.7276.72009/12/17HealthyN3949M4.79.7180.72009/12/17HealthyN4061M2.77.9225.22009/12/17HealthyN4143F3.411.7209.22009/12/17Healthy[^2]

Table A.2Description and ANOVA of 82 serum samples.Tumor markerSampleDescriptionANOVANumberAverageSDMinimumMaximumFSignificanceAFPHealthy413.11.21.46.33.100.08Patient414114.714,952.01.888,130.0AFUHealthy4118.16.07.933.517.080.00Patient4125.810.211.146.2FerritinHealthy41269.585.7109.4429.22.150.15Patient41246.155.5119.9358.4[^3]

Table A.3AFP detection result of 82 serum samples with IEB.SampleIEB results in gray-scale valueIEB results in concentration (ng/mL)Repeat 1Repeat 2Repeat 3AverageSDAverageSDH0191.193.092.792.31.08.71.4H0291.392.694.192.71.49.42.2H0392.694.395.294.01.311.82.6H0488.890.588.389.21.25.11.1H0590.092.189.990.71.26.61.5H0693.092.893.993.20.610.11.0H0787.186.588.987.51.23.80.9H0892.593.996.094.11.812.23.7H0991.491.791.891.60.27.70.3H1092.593.694.493.51.010.71.7H1196.095.398.496.61.618.45.4H1293.994.994.794.50.512.61.1H1394.496.797.096.01.416.73.8H1489.990.689.089.80.85.70.8H1597.697.998.898.10.61169.1127.8H1693.191.694.393.01.4988.9224.9H1788.790.391.990.31.66.31.7H1885.086.087.086.01.03.00.5H1986.485.388.486.71.63.40.9H2094.094.394.694.30.312.20.6H2190.088.389.489.20.9513.074.1H2299.2100.8100.6100.20.91681.3240.3H2388.889.890.889.81.02834.3484.1H2492.192.291.591.90.44051.7258.3H2581.280.082.081.11.02536.8428.8H2697.198.997.897.90.922.83.6H2771.473.372.272.31.05.60.9H2889.288.891.889.91.65901.11747.3H2995.695.095.095.20.3141.88.6H3094.595.294.394.70.5647.953.4H3190.489.691.290.40.86.30.9H32102.6104.6105.9104.41.73501.0959.0H3397.596.695.896.60.918.22.7H34101.2103.6104.1103.01.654.913.5H35105.4106.8105.8106.00.74535.1572.6H3694.694.594.994.70.212.90.5H3788.089.689.589.00.95.00.7H3887.285.887.386.80.83.40.5H3985.886.187.186.30.73.10.4H4093.092.491.692.30.78.71.0H4188.791.790.990.41.66.41.6N0187.889.088.888.50.64.50.5N0286.386.987.186.80.43.30.2N0385.686.885.485.90.82.90.4N0492.991.393.492.51.19.11.6N0586.187.787.387.00.83.50.5N0695.293.693.194.01.111.62.3N0786.789.390.188.71.84.81.3N0888.486.689.288.11.34.20.9N0988.188.391.089.11.65.11.5N1085.686.487.486.50.93.20.5N1188.090.190.589.51.35.51.2N1285.285.885.585.50.32.70.1N1389.189.090.589.50.85.40.8N1487.085.187.186.41.13.20.6N1589.191.489.790.11.26.01.3N1688.288.189.788.70.94.70.7N1788.787.088.488.00.94.20.6N1888.788.889.188.90.24.80.2N1989.989.991.990.61.26.51.3N2085.488.586.286.71.63.41.0N2185.086.385.385.50.72.70.3N2288.189.190.089.11.05.00.8N2390.490.391.590.70.76.60.8N2489.589.889.689.60.25.50.1N2589.891.289.690.20.96.10.9N2688.389.591.989.91.85.91.9N2786.387.286.886.80.53.30.3N2889.390.389.989.80.55.70.5N2987.890.490.989.71.75.71.5N3088.489.289.789.10.75.00.6N3186.385.786.486.10.43.00.2N3289.291.991.790.91.57.01.6N3388.788.890.889.41.25.31.1N3487.389.689.488.81.34.81.0N3584.786.586.085.70.92.80.4N3687.989.987.988.61.24.61.0N3787.486.787.287.10.43.50.2N3892.993.993.193.30.510.30.9N3988.491.690.890.31.76.21.7N4087.887.989.188.30.74.30.6N4188.787.790.488.91.44.91.2[^4][^5]

Table A.4AFU detection result of 82 serum samples with IEB.SampleIEB results in gray-scale valueIEB results in concentration (U/L)Repeat 1Repeat 2Repeat 3AverageSDAverageSDH01116.7117.4118.9117.71.116.11.7H02119.0121.0118.9119.61.219.42.2H03118.2118.3118.6118.40.217.20.3H04123.9123.6123.9123.80.228.40.5H05126.0126.1124.9125.70.733.92.1H06128.5130.8129.1129.51.248.35.5H07122.1123.0121.9122.30.624.81.4H08122.1121.7120.6121.50.822.91.6H09117.5116.7117.6117.30.515.50.7H10123.4123.8123.0123.40.427.41.0H11129.1130.8129.4129.80.949.64.3H12128.1128.6130.5129.11.346.65.6H13121.8121.6120.3121.20.822.41.7H14122.4122.8120.0121.71.523.63.2H15127.4127.1128.0127.50.540.11.7H16126.9126.3125.4126.20.835.62.5H17123.8122.5124.3123.50.927.82.4H18124.2126.3124.7125.11.132.13.3H19119.2119.6121.0119.90.919.91.8H20122.8124.1124.4123.80.928.42.2H21122.4121.4121.0121.60.723.21.6H22127.8129.9129.7129.11.246.94.9H23122.1119.7122.2121.31.422.72.9H24127.6127.8127.5127.60.240.60.6H25124.1124.7123.7124.20.529.41.4H26122.5120.6122.4121.81.123.82.3H27122.3121.5120.8121.50.823.11.6H28130.9128.3128.9129.41.448.06.2H29115.2115.2118.0116.11.614.02.2H30129.4128.8129.8129.30.547.62.2H31123.6121.1122.0122.21.324.72.9H32125.2125.4123.0124.51.330.63.6H33121.2121.0119.9120.70.721.31.4H34122.6122.1122.4122.40.324.90.6H35129.3131.2128.5129.71.449.36.5H36126.3124.0125.6125.31.232.83.5H37114.2114.5114.4114.40.211.80.2H38115.2117.7118.1117.01.615.22.1H39120.3119.2117.9119.11.218.52.1H40116.2118.2116.3116.91.115.01.6H41118.8119.0116.5118.11.416.82.1N01117.5117.5118.4117.80.516.30.8N02110.0112.3110.5110.91.28.61.0N03118.8118.5118.5118.60.217.50.3N04119.8118.0120.5119.41.319.02.2N05117.3118.3119.8118.51.317.42.1N06126.1127.4127.4127.00.838.22.6N07126.4126.0126.1126.20.235.40.7N08117.5119.5116.7117.91.416.52.3N09117.7119.6119.8119.01.218.31.9N10120.4119.9121.8120.71.021.42.0N11126.4127.2125.6126.40.836.32.7N12122.8123.1124.5123.50.927.62.4N13124.4122.9124.3123.90.828.72.2N14118.7120.4119.0119.40.918.91.6N15120.8118.9120.1119.91.019.91.8N16116.0117.5116.6116.70.814.71.0N17121.5120.2121.5121.10.822.11.5N18119.7120.1120.0119.90.219.90.4N19122.7121.3121.5121.80.823.71.7N20115.6117.7116.9116.71.114.81.4N21115.7115.8116.3115.90.313.70.4N22119.5119.9118.4119.30.818.71.3N23114.8115.6114.0114.80.812.30.9N24116.7117.5116.3116.80.614.90.9N25121.9122.2121.2121.80.523.61.1N26115.2115.0113.7114.60.812.10.9N27118.5116.6117.2117.41.015.81.4N28120.1120.5120.9120.50.420.90.8N29115.5117.2116.4116.40.914.31.1N30116.2117.2115.5116.30.914.21.1N31119.9119.2120.2119.80.519.60.9N32119.9119.9120.0119.90.119.80.1N33115.7116.6118.5116.91.415.12.0N34114.4114.7116.3115.11.012.71.2N35122.1123.1123.5122.90.726.21.7N36117.3118.9117.0117.71.016.21.6N37116.4116.9117.4116.90.515.00.7N38103.6103.1102.5103.10.64.10.2N39111.0111.5111.6111.40.39.00.3N40109.4108.8109.2109.10.37.30.2N41111.7110.8113.5112.01.49.51.2[^6]

Table A.5Ferritin detection result of 82 serum samples with IEB.SampleIEB results in gray-scale valueIEB results in concentration (ng/mL)Repeat 1Repeat 2Repeat 3AverageSDAverageSDH01102.9103.3104.5103.60.8277.937.6H02103.4104.1102.7103.40.7232.227.8H0398.9101.7101.6100.71.6149.837.2H0499.4101.3101.9100.91.3152.132.1H05103.3102.4104.1103.30.9227.532.9H06105.5105.2105.0105.20.3316.713.7H07102.8101.4101.8102.00.7182.823.1H08103.9101.7102.1102.61.2203.242.6H09104.2103.3105.8104.41.3280.462.2H10103.3102.9105.4103.91.3255.061.7H11102.0104.5104.3103.61.4243.553.7H1299.299.9101.1100.11.0131.722.1H13104.7104.5106.5105.21.1320.463.3H14102.9102.2104.1103.11.0220.336.9H1599.9102.2102.8101.61.5174.542.5H16101.8101.7103.8102.41.2198.642.4H17102.1103.2102.3102.50.6199.920.6H18103.2103.8102.7103.20.6225.321.3H19100.3102.0101.2101.20.9158.723.0H2098.999.6100.499.60.8121.815.7H21104.7104.2106.4105.11.2313.564.4H22103.8104.2103.9104.00.2254.89.2H23102.7103.5102.3102.80.6210.522.4H24102.9101.0103.1102.31.2195.036.4H25101.8102.6102.0102.10.4186.313.5H26101.3102.0104.0102.41.4199.749.9H27101.7102.3104.5102.81.5214.456.8H28104.3106.0107.0105.81.4353.079.7H29103.3106.1106.8105.41.9336.197.2H30106.9106.7106.8106.80.1414.07.1H31102.1100.5101.4101.30.8163.222.2H3298.199.497.198.21.296.019.1H33101.9103.4103.7103.01.0217.734.3H34100.1101.8100.1100.71.0146.125.6H35102.1100.4101.6101.40.9164.323.9H36103.5105.6106.4105.21.5319.677.2H37105.3104.6105.7105.20.6315.629.7H38103.7105.2104.6104.50.8280.635.8H39101.1102.1102.2101.80.6176.317.8H40103.0104.7103.6103.80.9247.937.3H41102.6104.2105.2104.01.3260.456.7N01102.0104.8104.0103.61.4243.957.0N02105.5105.0105.8105.40.4328.022.5N03102.3102.6103.7102.90.7212.127.5N04105.1103.9104.4104.50.6278.529.0N05102.6102.3102.0102.30.3191.69.8N06103.7104.9105.1104.60.8283.935.5N07104.0104.5104.2104.20.3266.811.6N08101.8103.2103.5102.80.9211.431.5N09107.5105.8108.7107.31.5463.0112.4N10103.8103.8104.6104.10.5259.721.0N11104.2103.0104.3103.80.7250.229.9N12104.8103.7104.1104.20.6265.925.7N13100.7103.2102.3102.11.3186.739.1N14100.9100.1101.2100.70.6146.814.0N15102.0102.5105.4103.31.8235.278.8N16100.9102.1102.4101.80.8176.723.2N1799.099.9101.8100.21.4137.134.6N18103.4104.9105.2104.51.0281.644.4N19102.6102.9103.9103.10.7221.826.5N20105.6103.3105.4104.81.3296.660.4N21101.6102.0103.3102.30.9192.930.3N22103.2102.6102.2102.70.5204.317.8N23105.1107.8106.7106.51.4402.691.1N24105.1105.8107.0106.01.0362.260.7N25100.7100.0101.3100.70.7145.316.1N26105.2106.4107.4106.31.1386.772.1N27105.7103.6103.9104.41.1278.056.6N28104.7103.8106.6105.01.4312.178.9N29104.2104.5102.4103.71.1246.345.2N30101.7101.1102.9101.90.9180.228.9N3197.298.197.397.50.584.77.3N3299.2102.499.8100.51.7144.044.4N33103.0100.8103.7102.51.5202.449.1N34102.1102.3102.9102.40.4196.214.2N35104.5105.3106.7105.51.1335.465.3N3699.598.2100.499.41.1117.121.7N3797.298.696.897.50.985.314.3N38102.5104.2104.4103.71.0245.841.6N3998.899.299.699.20.4112.77.7N40103.2103.4102.7103.10.4219.813.4N41101.4102.8102.7102.30.8192.524.7[^7][^8]
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[^1]: In the regression equations, y is IEB result in gray-scale value and x presents tumor marker concentration.

[^2]: HCC +: hepatocellular carcinoma patients. The units of AFP, AFU and ferritin concentrations are mg/mL, U/L and mg/mL, respectively.

[^3]: ANOVA: analysis of variance. SD: standard deviation.

[^4]: SD: standard deviation.

[^5]: Due to the detection range, samples H15, H16, H22, H23, H24, H25, H27, H28, H29, H30, H32 and H35 have been diluted before detection.

[^6]: SD: standard deviation.

[^7]: SD: standard deviation.

[^8]: Due to the detection range, all samples have been diluted to 4 times before detection.
